Patrys Ltd., of Melbourne, Australia, reported preclinical data showing that its PAT-DX1, a humanized version of Deoxymab 3E10, acts synergistically with PARP inhibitor Lynparza (olaparib, Astrazeneca plc). Combinations of PAT-DX1 and olaparib were tested on both brain and colon cancer cells with defective DNA repair pathways.